HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

pirinixic acid

Subscribe to New Research on pirinixic acid

structure

Also Known As:

(4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; 4-chloro-6-(2,3-dimethylphenyl)amino-2-pyrimidinylthioacetic acid; 4-chloro-6-(2,3-xylidinyl)-2-pyrimidinylthioacetic acid; CXPTA; WY 14,643; WY-14,643; WY14,643; Wy 14643; Wy-14643; Wyeth 14,643; Wyeth-14643; acetic acid, ((4-chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)-

Networked: 119 relevant articles (7 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 319
    - pirinixic acid: 119

Experts

1.	Gonzalez, Frank J: 5 articles (02/2014 - 04/2008)
2.	Cuzzocrea, Salvatore: 5 articles (01/2010 - 07/2002)
3.	Shah, Yatrik M: 4 articles (02/2014 - 04/2008)
4.	Mazzon, Emanuela: 4 articles (01/2010 - 10/2004)
5.	Di Paola, Rosanna: 4 articles (01/2010 - 10/2004)
6.	König, Bettina: 4 articles (03/2009 - 11/2006)
7.	Stangl, Gabriele I: 4 articles (03/2009 - 11/2006)
8.	Eder, Klaus: 4 articles (03/2009 - 11/2006)
9.	Koch, Alexander: 4 articles (03/2009 - 11/2006)
10.	Sugden, Mary C: 4 articles (02/2003 - 06/2002)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2015 - "Although PPARα(Δ)ob/ob mice are severely obese, there was no significant increase in liver tumor incidence, even when maintained on a diet containing Wy-14,643. " 04/01/2006 - "Wy-14,643 (WY) is a hypolipidemic drug that induces hepatic peroxisome proliferation and tumors in rodents. " 04/01/2001 - "The potent PP and rodent tumor promoter, pirinixic acid (WY-14643) also inhibited LXR-mediated transcription in a dose related manner (approximate IC(50) of 100 microM). " 01/01/2000 - "In in vivo experiments, the formation of preneoplastic lesions and the tumors caused by Wy-14,643 administration were markedly suppressed by i.v.-injection of HGF in a dose-dependent manner. " 01/01/1994 - "Induction of a 65-kDa tumor-associated protein in altered hepatic foci of rats fed the peroxisome proliferator Wy-14,643."
2.	Hepatomegaly 12/01/2010 - "VP16PPARα mice exhibited massive peroxisome proliferation and hepatomegaly as well as increased mortality upon Wy-14,643 treatment. " 06/01/2001 - "Hepatomegaly was found in both HGF transgenic mouse lines fed WY-14,643 compared with controls. " 01/01/2001 - "When the potent peroxisome proliferator, WY-14,643, was given to hypothyroid rats, there was a blunting of the hepatomegaly and hepatocyte proliferative responses seen in thyroid-intact animals. " 01/01/1992 - "Hepatomegaly was induced by Wy-14,643 at all doses and at all time points. " 11/06/1995 - "In a 42-day study, dietary concentrations of 0.9-2.0% gemfibrozil induced a similar magnitude of hepatomegaly to WY-14,643 (2.3-fold) but a higher level of peroxisome proliferation (16-18-fold) than the maximum induction for WY-14,643 (13-fold). "
3.	Fatty Liver 05/01/2004 - "In conclusion, the present study shows that MCD diet-induced fibrosing steatohepatitis can be reversed by treatment with Wy-14,643. " 05/01/2009 - "Importantly, WY-14,643 reversed the development of fatty liver in alcohol-fed mice. " 07/01/2003 - "Wy-14,643 prevented rather than increased liver injury; ALT levels were only mildly elevated whereas steatohepatitis was absent. " 05/01/2004 - "We have now tested whether Wy-14,643 ameliorates established steatohepatitis and fibrosis. " 01/01/2015 - "PPARα Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury."
4.	Inflammation 07/05/2013 - "To address the beneficial efficacy of Wy-14643 for ALI along with systemic inflammation, the in vivo role of PPARα activation was investigated in a mouse model of lipopolysaccharide (LPS)-induced ALI. " 12/01/2005 - "Moreover, Wy-14,643 treatment reduced inflammation and the expression of macrophage-specific genes in white adipose tissue (WAT). " 10/01/2009 - "Pirinixic acid (Wy-14,643) is an agonist of the peroxisome proliferator-activated receptor (PPAR) subtype alpha exhibiting beneficial effects in various inflammation-related processes in a slow, long-termed fashion. " 01/01/2015 - "Activation of peroxisome proliferator-activated receptor-α (PPAR-α) by fibrates, such as WY-14643 (WY), has been described to beneficially influence inflammation and experimental lung injury. "
5.	Acute Lung Injury 07/05/2013 - "Activation of PPARα by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury." 11/01/2008 - "Activation of peroxisome proliferator-activated receptor-alpha by WY 14,643 reduced acute lung injury and vascular leakage. "

Related Drugs and Biologics

1.	PPAR alpha
2.	Glycine (Aminoacetic Acid)
3.	Peroxisome Proliferator-Activated Receptors (PPAR)
4.	Carcinogens
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	ragaglitazar
7.	Clofibrate
8.	pirinixic acid
9.	troglitazone (Rezulin)
10.	Matrix Metalloproteinase 9 (Gelatinase B)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)